Female breast central part cancer

Summary

Female breast central part cancer (MONDO:0001805) is a cancer. A subtype of female breast carcinoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	female breast central part cancer
Mondo ID	MONDO:0001805
DOID	DOID:13799
SNOMED CT	188151006
UMLS	C0153549
MedGen	509323
Is cancer (heuristic)	yes

Also known as: malignant neoplasm of central portion of female breast

Disease family

This is a subtype of female breast carcinoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › carcinoma › breast carcinoma › female breast carcinoma › female breast central part cancer

Related subtypes (6): female breast nipple and areola cancer, female breast lower-outer quadrant cancer, female breast upper-inner quadrant cancer, female breast lower-inner quadrant cancer, female breast axillary tail cancer, female breast upper-outer quadrant cancer

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.